Search - tctmd.com

Displaying 341 - 360 of 480

Sort: Relevancy | Date

Presentation

Amiodarone, Anticoagulation, and Clinical Events in Patients with A-fib: Insights from ARISTOTLE

Presenter: Greg Flaker

October 07, 2014

Presentation TCT 2014

Thoughtful Insights

Presenter: Pascal Vranckx

September 17, 2014

Presentation TCT 2014

Case Presentation

Presenter: Matthew J. Price

September 17, 2014

Presentation TCT 2014

Thoughtful Insights

Presenter: Daniel I. Simon

September 17, 2014

Presentation TCT 2014

Case Presentation

Presenter: Thomas D. Stuckey

September 17, 2014

Presentation TCT 2014

Thoughtful Insights

Presenter: Neal S. Kleiman

September 17, 2014

Presentation TCT 2014

Case Presentation

Presenter: Frederick Kushner

September 17, 2014

Presentation TCT 2014

Sudden Cardiac Death and Atrial Fibrillation in HCM

Presenter: John S. Douglas Jr, Sherif F. Nagueh, Howard C. Herrmann, Kishore J. Harjai

September 16, 2014

Presentation TCT 2014

Cost-effectiveness Analysis Of Left Atrial Appendage Occlusion Device Compared With 7 Oral Anticoagulants For Stroke Prevention In Atrial Fibrillation

Presenter: Vivian Lee

September 16, 2014

Presentation TCT 2014

TCT 170: Cost-effectiveness Analysis of a Left Atrial Appendage Occlusion Device Compared with 7 Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation

Presenter: Saibal Kar, Bushra S Rana, Jai-Wun Park, Vivian Lee

September 15, 2014

Presentation TCT 2014

TCT 475: Triple Antithrombotic Therapy Versus Dual Antiplatelet Therapy in Patients with Atrial Fibrillation Undergoing Drug-Eluting Stent Implantation

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Dong Oh Kang

September 15, 2014

Presentation TCT 2014

TCT 474: Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndromes: The AVIATOR Registry

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Georgios Christodoulidis

September 15, 2014

Presentation TCT 2014

Edoxaban in ACS and Atrial Fibrillation: Risk/Benefit Analysis and Future Directions

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Michael D. Ezekowitz

September 15, 2014

Presentation TCT 2014

Apixaban in ACS and Atrial Fibrillation: Comparison to Warfarin and Aspirin

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Christopher B. Granger

September 15, 2014

Presentation TCT 2014

Rivaroxaban in ACS and Atrial Fibrillation: Randomized Trials, Real-World Data, and Pioneering Efforts

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson

September 15, 2014

Presentation TCT 2014

Dabigatran in ACS and Atrial Fibrillation: MI Risks, Safety in the Elderly, and the RE-DUAL Trial

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Laura Mauri

September 15, 2014

Presentation TCT 2014

Current (and Future) Guidelines for Atrial Fibrillation Treatment

Presenter: Josep Rodés-Cabau, Brian K. Whisenant, David Hildick-Smith, Ted E. Feldman

September 15, 2014

Presentation TCT 2014

Stroke, Bleeding, and Risk Scores in Atrial Fibrillation

Presenter: Josep Rodés-Cabau, Brian K. Whisenant, David Hildick-Smith, Stefan C. Bertog

September 15, 2014

Presentation TCT 2014

Putting it All Together: Anticoagulants, Rhythm Control, and LAA Closure Which Therapy for Which Patient?

Presenter: Matthew J. Price, Shephal Doshi

September 15, 2014

Presentation TCT 2014

Shifting the Treatment Paradigm with LAA Closure: Efficacy, Complications, and Future Challenges

Presenter: Matthew J. Price

September 15, 2014

Advertisement

Amiodarone, Anticoagulation, and Clinical Events in Patients with A-fib: Insights from ARISTOTLE

Thoughtful Insights

Case Presentation

Thoughtful Insights

Case Presentation

Thoughtful Insights

Case Presentation

Sudden Cardiac Death and Atrial Fibrillation in HCM

Cost-effectiveness Analysis Of Left Atrial Appendage Occlusion Device Compared With 7 Oral Anticoagulants For Stroke Prevention In Atrial Fibrillation

TCT 170: Cost-effectiveness Analysis of a Left Atrial Appendage Occlusion Device Compared with 7 Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation

TCT 475: Triple Antithrombotic Therapy Versus Dual Antiplatelet Therapy in Patients with Atrial Fibrillation Undergoing Drug-Eluting Stent Implantation

TCT 474: Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndromes: The AVIATOR Registry

Edoxaban in ACS and Atrial Fibrillation: Risk/Benefit Analysis and Future Directions

Apixaban in ACS and Atrial Fibrillation: Comparison to Warfarin and Aspirin

Rivaroxaban in ACS and Atrial Fibrillation: Randomized Trials, Real-World Data, and Pioneering Efforts

Dabigatran in ACS and Atrial Fibrillation: MI Risks, Safety in the Elderly, and the RE-DUAL Trial

Current (and Future) Guidelines for Atrial Fibrillation Treatment

Stroke, Bleeding, and Risk Scores in Atrial Fibrillation

Putting it All Together: Anticoagulants, Rhythm Control, and LAA Closure Which Therapy for Which Patient?

Shifting the Treatment Paradigm with LAA Closure: Efficacy, Complications, and Future Challenges

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content